0000000000037640

AUTHOR

Lorenzo Scalise

showing 2 related works from this author

Wireless ECG and cardiac monitoring systems: State of the art, available commercial devices and useful electronic components

2021

Abstract Wireless ElectroCardioGram (ECG) systems are employed in manifold application fields: tele-monitoring, sport applications, support to ageing people at home, fetal ECG, wearable devices and ambulatory monitoring. The presence of cables often hinders user’s free movements, alongside clinicians’ routine operations. Therefore, wireless ECG systems are desirable. This paper aims at reviewing the solutions described in the literature, besides commercially available devices and electronic components useful to setup laboratory prototypes. Several systems have been developed, different in terms of the adopted technology; when approaching the development of a wireless ECG system, some import…

Computer scienceElectrodemedicine.medical_treatmentWireless communication02 engineering and technology01 natural sciencesMultiplexerlaw.inventionBluetoothElectrocardiographyData acquisitionlawSettore ING-IND/12 - Misure Meccaniche E Termiche0202 electrical engineering electronic engineering information engineeringmedicineMiniaturizationWirelessElectrical and Electronic EngineeringInstrumentationWearable technologyECGbusiness.industryApplied Mathematics020208 electrical & electronic engineering010401 analytical chemistryCondensed Matter Physics0104 chemical sciencesvisual_artElectronic componentvisual_art.visual_art_mediumWireless ECGCardiac monitoringbusinessBiomedical engineeringComputer hardwareMeasurement
researchProduct

Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma

2022

Inhibitors of the Bromo- and Extra-Terminal domain (BET) family proteins have strong preclinical antitumor activity in multiple tumor models, including lymphomas. Limited single-agent activity has been reported in the clinical setting. Here, we have performed a pharmacological screening to identify compounds that can increase the antitumor activity of BET inhibitors in lymphomas. The germinal center B-cell like diffuse large B-cell lymphoma (DLBCL) cell lines OCI-LY-19 and WSU-DLCL2 were exposed to 348 compounds given as single agents at two different concentrations and in combination with the BET inhibitor birabresib. The combination partners included small molecules targeting important bi…

LYMPHOMASHDACLRRK2General MedicineBETJAKeJHaem
researchProduct